- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05741242
Basket Trial van neoantigen synthetische lange peptidevaccins bij patiënten met gevorderde maligniteit
A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a Simon-two stage multi-cohort study to assess the safety and efficacy of neoantigen synthetic long peptide vaccines in patients with local or metastatic solid tumors.
- To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).
- To assess efficacy of NeoSLP vaccination by assessment of Time to Treatment Failure (TTF).
- To assess efficacy of NeoSLP vaccination by assessment of Overall Survival at 24 months (OS24).
- To investigate the immunogenicity of NeoSLP vaccines by ELISpot assay. 5. To assess the safety and tolerability of NeoSLP vaccines.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
California
-
Beverly Hills, California, Verenigde Staten, 90212
- Precision NextGen Oncology & Research Center
-
San Francisco, California, Verenigde Staten, 94115
- Quest Clinical Research
-
Santa Monica, California, Verenigde Staten, 90403
- Asthra Health
-
-
Florida
-
Miami Beach, Florida, Verenigde Staten, 33140
- Mount Sinai Comprehensive Cancer Center
-
-
Missouri
-
Bridgeton, Missouri, Verenigde Staten, 63044
- St. Louis Cancer Care
-
-
New York
-
New York, New York, Verenigde Staten, 10028
- Anna Gattani MD PC
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Patients must satisfy the following criteria to be enrolled in the protocol:
Main Inclusion Criterion:
Pancreatic
- Patients who have local or metastatic pancreatic adenocarcinoma and have started first line therapy of Folfirinox (physician's choice for any concomitant therapies)
- Patients who have undergone somatic tumor sequencing should consider FDA-approved pan-solid tumor therapies if they harbor an FDA-approved somatic alteration. For example, Entrectinib or Larotrectinib (if NTRK gene fusion- positive), Selpercatinib (if RET gene fusion-positive), Pembrolizumab (if MSI-H, dMMR, or TMB-H[≥10 mut/Mb]), and PARP inhibitors (BRCA mutations).
Glioblastoma
1. Patients who are within 6 months of diagnosis and have detectable disease as determined by investigator assessment at the start of vaccine administration.
Basket
1. Patients with local or metastatic malignancies, limited treatment options, and an estimated 5-year survival of less than 50% are eligible for enrollment in this cohort.
Other Inclusion Criteria:
- >= 12 years of age.
- ECOG performance status ≤ 2 or Karnofsky score of >=70.
- Adequate organ function allowing favorable benefit to risk ratio per the treating physician
- Systemic corticosteroid therapy is permitted provided dosing is no greater than 4 mg per day (dexamethasone or equivalent) on the day of vaccine administration.
- Ability to understand and willingness to sign an IRB approved written informed consent document.
Exclusion Criteria:
- History of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty or known allergy to a component of the neoantigen synthetic long peptide vaccine.
- Intercurrent illness requiring chronic use of medications that may interfere with rescue medications for treatment of vaccine-related anaphylaxis or attenuate immune response to vaccine treatment (immunosuppressive therapies).
- Psychiatric illness or social situations that would limit compliance with study requirements.
- History of pre-existing immunodeficiency disorder or autoimmune condition requiring immunosuppressive therapy that would preclude response to vaccine.
- Females of childbearing potential may participate provided they agree to practice abstinence; and, if heterosexually active, agree to use at least 2 highly effective contraceptive methods throughout the study and for 3 months following the last dose of study drug; and have a negative serum pregnancy test.
- Females of non-childbearing potential must be post-menopausal or have been surgically sterilized.
- Male subjects with a female partner of childbearing potential must agree to practice abstinence or to use a physician-approved contraceptive method throughout the study and for 3 months following the last dose of study drug.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Gepersonaliseerd synthetisch vaccin met lange peptiden
|
Personalized Synthetic Long Peptide Vaccine |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To assess the efficacy of NeoSLP vaccination by investigator assessment of Progression-Free Survival at 12 months (PFS12).
Tijdsspanne: Until progression or death, assessed up to 12 months post first vaccine administration.
|
Progression-Free Survival at 12 months (PFS12) defined as time from first vaccine administration until disease progression by investigator assessment or death due to any cause. |
Until progression or death, assessed up to 12 months post first vaccine administration.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To assess efficacy of NeoSLP vaccination by assessment of Time to Treatment Failure (TTF).
Tijdsspanne: Assessed up to 12 months post first vaccine administration
|
Time to Treatment Failure (TTF) is defined as time from first vaccine administration to discontinuation of treatment due to any reason, including disease progression, treatment toxicity, and death. |
Assessed up to 12 months post first vaccine administration
|
|
To assess efficacy of NeoSLP vaccination by assessment of Overall Survival at 24 months (OS24).
Tijdsspanne: Until death, assessed up to 24 months post first vaccine administration
|
Overall Survival at 24 months (OS24) is the landmark of OS defined as the proportion of patients alive at 24 months. |
Until death, assessed up to 24 months post first vaccine administration
|
|
To assess the safety and tolerability of NeoSLP vaccines.
Tijdsspanne: Assessed up to 60 days from last vaccine administration
|
Adverse Events (AEs) and Severe Adverse Events (SAEs) |
Assessed up to 60 days from last vaccine administration
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
To investigate the immunogenicity of NeoSLP vaccines by ELISpot assay.
Tijdsspanne: Assessed at baseline before first vaccine administration and day 50 post
|
Immune monitoring is defined as the percentage of patients showing an immune response to the vaccine components. |
Assessed at baseline before first vaccine administration and day 50 post
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- JLF-200
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .